In This Article:
Over the last 7 days, the Australian market has dropped 1.7%, driven by a decline of 5.4% in the Materials sector, although it remains up 10% over the past year with earnings expected to grow by 12% per annum over the next few years. In this context, identifying high-growth tech stocks that can outperform despite short-term market fluctuations is crucial for investors seeking robust long-term returns.
Top 10 High Growth Tech Companies In Australia
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Clinuvel Pharmaceuticals | 22.41% | 27.42% | ★★★★★★ |
| Pureprofile | 14.94% | 80.73% | ★★★★★☆ |
| AVA Risk Group | 32.56% | 118.83% | ★★★★★★ |
| ImExHS | 20.47% | 111.20% | ★★★★★★ |
| DUG Technology | 10.90% | 32.21% | ★★★★★☆ |
| Pointerra | 56.62% | 126.45% | ★★★★★★ |
| Careteq | 34.13% | 126.60% | ★★★★★☆ |
| Wrkr | 36.31% | 100.29% | ★★★★★★ |
| Adveritas | 57.98% | 144.21% | ★★★★★★ |
| SiteMinder | 19.39% | 60.31% | ★★★★★☆ |
Click here to see the full list of 62 stocks from our ASX High Growth Tech and AI Stocks screener.
Underneath we present a selection of stocks filtered out by our screen.
Opthea
Simply Wall St Growth Rating: ★★★★★☆
Overview: Opthea Limited is a clinical-stage biopharmaceutical company focused on developing and commercializing drugs for eye diseases in Australia and the United States, with a market cap of A$750.97 million.
Operations: Opthea Limited generates revenue primarily from its medical technology and healthcare segment, amounting to $0.26 million. The company is engaged in the development and commercialization of drugs targeting eye diseases within Australia and the United States.
Opthea's strategic focus on wet AMD treatments, particularly sozinibercept, is bolstered by robust R&D investments. With revenue projected to grow at 51.6% annually and earnings expected to surge by 61.1% per year, the company is positioning itself for significant future gains. Recent executive changes aim to leverage extensive industry expertise, enhancing commercial and clinical operations. Despite a net loss of $220.24 million in FY2024, Opthea's commitment to innovation and market expansion reflects its high-growth potential within Australia's tech landscape.
-
Click here to discover the nuances of Opthea with our detailed analytical health report.
-
Evaluate Opthea's historical performance by accessing our past performance report.
Pro Medicus
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Pro Medicus Limited is a healthcare informatics company that develops and supplies imaging software and radiology information system (RIS) software and services to hospitals, imaging centers, and healthcare groups in Australia, North America, and Europe, with a market cap of A$16.59 billion.